In my January 30, 2025 post, I recommended buying undervalued Danaher (DHR) shares amid market challenges. Following that post, shares were caught in the recent broad market pullback. In early April, DHR's share price fell as low as ~$172. Despite a mild recovery to ~$196.50 as I compose this post on April 24, I still [...]
In my November 3, 2024 Thermo Fisher Scientific (TMO) post, I stated 'I think there will be an opportunity to acquire shares at a more favorable valuation within the next 12 months'. TMO shares were trading @ ~$558. Within days of that post, TMO's share price plunged thus contributing to an improvement in its valuation. [...]
A strong case for investing in BlackRock (BLK) can be made when markets implode. It is the world's largest asset manager with over $11.5 TRILLION of Assets Under Management (AUM). In prior Brookfield (BN.to), Blackstone (BX), and BlackRock (BLK) posts, I stated that the asset management industry is saturated and that a 'shake-out' is imminent. [...]
In my recent Corrections Are Healthy post, I reference Rudyard Kipling's poem 'If'. I mention that the segments from the poem that resonate the most with me are: If you can keep your head when all about you are losing theirs If you can wait and not be tired by waiting After publishing that post [...]
To the best of my ability, I try to provide the timely disclosure of my investment activity. In my April 3 Blackstone and Brookfield Exposure Increase post, I disclose purchases in those two companies. With the April 7 Mastercard (MA), S&P Global (SPGI), and HEICO Corporation (HEI and HEI.a) exposure increases, I now disclose these [...]
Some investors perform discounted cash flow analyses when trying to assess a company’s outlook. Perhaps these calculations help them justify their investment decisions. I, however, get absolutely no value from performing these calculations and came to this realization in the mid-1980s while attending a Master of Business Administration (MBA) program at university. My finance professors [...]
We are certainly living in 'interesting times'. As investors, we can either 'panic' or view them as an 'opportunity'. I view the April 2 tariff announcement as an 'opportunity'. A HUGE segment of the global population is, unfortunately, going to be in a 'world of hurt'. The same applies to a great many companies whose [...]
In my December 19, 2024 post I disclose initiating a 300 share Cintas (CTAS) position in one of the 'Side' accounts in the FFJ Portfolio. I subsequently acquired an additional 200 shares on December 31, 2024 thereby bringing my total exposure to 500 shares. Although CTAS is in an entirely different industry than Rollins (ROL), [...]
Another month has flown by thus triggering this FFJ Portfolio - March 2025 report; all monthly reports are accessible here. At the end of every post, I include the 'I do not know your circumstances and am not providing individualized advice or recommendations' disclaimer. I want to ensure everyone reading my posts has no preconceived [...]
Following my October 2, 2024 post at which time the most currently available financial information was for Q1 2025, Paychex (PAYX) disclosed its intent to acquire Paycor HCM (PYCR) for ~$4.1B on January 7, 2025. PAYX expects to close this acquisition in April 2025. This impending acquisition makes strategic sense as it enables PAYX to expand [...]